Synergism of KRAS G12C Inhibitor and mTOR Inhibitor in Lung Adenocarcinoma and Squamous Cell Carcinoma

被引：0
|
作者：
Ito, M. [1 ,2 ]
Miyata, Y. [2 ]
Hirano, S. [2 ]
Morihara, N. [2 ]
Irisuna, F. [2 ]
Takemoto, M. [2 ]
Tsutani, Y. [1 ]
Okada, M. [2 ]
机构：
[1] Kindai Univ, Osaka, Japan
[2] Hiroshima Univ, Hiroshima, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
KRAS; mTOR; squamous cell carcinoma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP02.01-09
引用
收藏
页码：S429 / S429
页数：1
相关论文
共 50 条
  • [1] Targeting KRAS G12C mutation in lung adenocarcinoma
    Rohatgi, Anjali
    Govindan, Ramaswamy
    [J]. LUNG CANCER, 2022, 165 : 28 - 33
  • [2] The MET Inhibitor Tepotinib Potentially Inhibits KRAS G12C and SHOC2 in KRAS G12C Non-Small Cell Lung Cancer (NSCLC)
    Rosell, R.
    Jain, A.
    Codony-Servat, J.
    Shivamallu, C.
    Kollur, S. Prasad
    Prasad, A.
    Jantus-Lewintre, E.
    Ito, M.
    Cardona, A. F.
    Arrieta, O.
    Cao, P.
    Cai, X.
    Xing, B.
    Pedraz-Valdunciel, C.
    Dantes, Z.
    Sullivan, I.
    Aguilar, A.
    Molina-Vila, M. A.
    Gonzalez-Cao, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S112 - S112
  • [3] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
    Adachi, Yuta
    Ito, Kentaro
    Kimura, Ryo
    Yamaguchi, Rui
    Ebi, Hiromichi
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
  • [4] Adagrasib: a novel inhibitor for KRAS(G12C)-mutated non-small-cell lung cancer
    Guo, Matthew Z.
    Marrone, Kristen A.
    Spira, Alexander
    Rosner, Samuel
    [J]. FUTURE ONCOLOGY, 2023, 19 (15) : 1037 - 1051
  • [5] Antitumor Effect of the KRAS G12C Inhibitor Sotorasib combined with Radiotherapy and Carboplatin/Cisplatin in human Lung Carcinoma Cell Lines
    Maltzahn, Christin
    Patties, Ina
    Kortmann, Rolf-Dieter
    Seidel, Clemens
    Glasow, Annegret
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2023, 199 : S101 - S101
  • [6] ONCOGENIC KRAS G12C MUTATION DERIVED INHIBITOR DEVELOPMENT
    Leveles, Ibolya
    Koppany, Gergely
    Nyiri, Kinga
    Vertessy, G. Beata
    [J]. ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2019, 75 : E117 - E117
  • [7] Selinexor (XPO1 inhibitor) in combination with tepotinib (MET inhibitor) potentially inhibits SHOC2 and KRAS G12C in KRAS G12C mutant non-small cell lung cancer
    Rosell, R.
    Jain, A.
    Codony-Servat, J.
    Shivamallu, C.
    Kollur, S. P.
    Prasad, A.
    Vishwanath, P.
    Jantus Lewintre, E.
    Ito, M.
    Cardona Zorrilla, A. F.
    Arrieta Rodriguez, O. G.
    Pedraz-Valdunciel, C.
    Gonzalez Nieto, J.
    Aguilar, A.
    Molina-Vila, M. A.
    Gonzalez Cao, M.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1188 - S1188
  • [8] KRAS G12C inhibitor combination therapies: current evidence and challenge
    Miyashita, Hirotaka
    Kato, Shumei
    Hong, David S.
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
  • [9] Process Research for ZG1077, a KRAS G12C Inhibitor
    Feng, Wei-Dong
    Lv, Bin-Hua
    Ye, Wei
    Wang, Cai
    Jin, Lin-Yong
    Wang, Run-Qing
    Lian, Chang-Min
    You, Kuan-Hong
    [J]. ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2022, 26 (10) : 2986 - 2996
  • [10] RESISTANT KRAS(G12C) INHIBITOR SUBCLONES EXHIBIT HETEROGENEOUS ALTERATIONS
    不详
    [J]. CANCER DISCOVERY, 2022, 12 (01) : 13 - 13
12345